NEXTCURE, INC

NXTC ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2020 FY2019
Revenue $22.4M $6.3M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $46.6M $34.2M
SG&A Expense $17.0M $9.6M
Operating Income $-41.2M $-37.5M
Operating Margin -184.2% -590.5%
Interest Expense $183.0K $209.0K
Pretax Income
Income Tax Expense
Net Income $-36.6M $-33.7M
Net Margin -163.6% -531.5%
EPS (Basic) $-1.33 $-2.15
EPS (Diluted) $-1.33 $-2.15
Shares Outstanding (Basic) 27.5M 27.5M
Shares Outstanding (Diluted) 27.5M 27.5M
Dividends Per Share $0.00 $0.00